Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1998 3
1999 4
2000 2
2001 2
2002 2
2003 1
2004 1
2005 3
2006 2
2007 4
2008 2
2009 1
2010 2
2011 4
2012 7
2013 7
2014 5
2015 9
2016 7
2017 7
2018 2
2019 8
2020 8
2021 9
2022 12
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

107 results
Results by year
Filters applied: . Clear all
Page 1
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: soubeyran i. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: soubeyran i. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Teyssonneau D, et al. Among authors: soubeyran i. J Hematol Oncol. 2021 Mar 29;14(1):51. doi: 10.1186/s13045-021-01061-x. J Hematol Oncol. 2021. PMID: 33781305 Free PMC article. Review.
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Larroquette M, et al. Among authors: soubeyran i. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. J Immunother Cancer. 2022. PMID: 35618288 Free PMC article.
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Cousin S, et al. Among authors: soubeyran i. Eur J Cancer. 2022 Feb;162:161-169. doi: 10.1016/j.ejca.2021.11.012. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998048 Clinical Trial.
Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I. Callens C, et al. Among authors: soubeyran i. J Natl Cancer Inst. 2021 Jul 1;113(7):917-923. doi: 10.1093/jnci/djaa193. J Natl Cancer Inst. 2021. PMID: 33372675 Free PMC article. Clinical Trial.
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial.
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy F, Souquet PJ, Cloarec N, Giroux-Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B. Barlesi F, et al. Among authors: soubeyran i. Clin Cancer Res. 2022 Sep 15;28(18):4018-4026. doi: 10.1158/1078-0432.CCR-22-0371. Clin Cancer Res. 2022. PMID: 35802649 Clinical Trial.
[Oesogastric cancer - new therapeutic targets].
Palmieri LJ, Soubeyran I, Pernot S. Palmieri LJ, et al. Among authors: soubeyran i. Bull Cancer. 2022 Nov 9:S0007-4551(22)00340-X. doi: 10.1016/j.bulcan.2022.08.005. Online ahead of print. Bull Cancer. 2022. PMID: 36371284 Review. French.
[Update on lymphomas].
Eghbali H, Soubeyran P, Soubeyran I, Monnerau A, Cazorla S. Eghbali H, et al. Among authors: soubeyran i. Bull Cancer. 2002 Jan;89(1):89-99. Bull Cancer. 2002. PMID: 11847030 Free article. Review. French.
Therapeutic strategies in elderly and very elderly patients.
Soubeyran P, Henriques de Figueiredo B, Soubeyran I, Mertens C, Cazeau AL. Soubeyran P, et al. Among authors: soubeyran i. Best Pract Res Clin Haematol. 2012 Mar;25(1):91-100. doi: 10.1016/j.beha.2012.01.009. Epub 2012 Feb 22. Best Pract Res Clin Haematol. 2012. PMID: 22409826 Review.
107 results